STOCK TITAN

Teva R&D chief Eric Hughes to step down immediately

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, will leave the company after accepting an offer outside Teva. He will step down from his role immediately and assist with the transition over the coming months.

David Gardiner, MD, will serve as R&D transition lead effective immediately, reporting directly to President and CEO Richard Francis until a permanent successor is named. Teva is initiating a comprehensive search for a successor.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Innovative medicines revenue ambition $6–7 billion Teva's ambition for 2030
biosimilars medical
"complex generic medicines, biosimilars, and pharmacy brands worldwide"
Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Teva (TEVA)'s 2030 innovative medicines revenue ambition?

Teva's stated ambition is to generate $6–7 billion in innovative medicines revenue by 2030, as part of the commitments outlined at its R&D Day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000081868600-000000000008186862026-11-172026-11-17

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 17, 2026

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

Israel

 

001-16174

 

Not Applicable

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

400 Interpace Parkway, #3

Parsippany NJ, 07054 USA

+1-973-658-0301

(Address of principal executive offices, zip code and telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary Shares, par value NIS 0.1 per share

 

TEVA

 

New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer

On November 17, 2026, Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, notified Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) of his intention to resign. Dr. Hughes will step down immediately from his role and will continue to assist with a smooth transition over the next few months.

 

ITEM 7.01

Regulation FD Disclosure

On November 18, 2026, Teva issued a press release announcing that Dr. Eric Hughes will be leaving Teva. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing.

 


ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

 

 

 

Exhibit

 

Description of Document

 

 

99.1

 

Press release of the Company issued on November 18, 2026.

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

 

 

 

 

 

Date: November 18, 2026

By:

/s/ Eli Kalif

 

 

 

 

 

Name: Eli Kalif

 

 

Title: Executive Vice President,

 

 

            Chief Financial Officer



 

 


img154009353_0.jpg

 

 

img154009353_1.jpg Exhibit 99.1

Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company

 

Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor

 

TEL AVIV, Israel and PARSIPPANY, N.J., November 18, 2026 (GLOBE NEWSWIRE) Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, has decided to leave Teva and has accepted an offer outside the company. Dr. Hughes will remain with Teva through the coming months to support a seamless transition.

 

Effective immediately, David Gardiner, MD, Head of Innovative Medicines & Clinical Development, will serve as transition lead for R&D, reporting directly to Teva's President and Chief Executive Officer, Richard Francis, until a permanent successor is named. Teva is initiating a comprehensive search for a successor beginning immediately.

 

“Eric has made critical contributions to Teva and to the transformation of our R&D organization,” said Richard Francis, President and CEO of Teva. “He has helped build the pipeline, capabilities, and organization we presented at R&D Day last week and leaves Teva well positioned for its next chapter. Our strategy, priorities and expectations have not changed, and our focus remains on executing against the commitments we have made and continuing the momentum across our innovative pipeline.”

 

“I am incredibly proud of what our R&D organization accomplished to establish Teva as a truly innovative biopharma company and of the strong team we built,” said Dr. Hughes. “The progress we shared at R&D Day reflects the strength and depth of this organization and the exceptional science we developed together. I am deeply grateful to the entire team for their dedication, talent and partnership. It has been a privilege to lead them.”

 

Teva's R&D strategy and priorities remain unchanged, and the company remains focused on delivering on the commitments outlined in its November 11th R&D Day, including its ambition to generate $6–7 billion in innovative medicines revenue by 2030.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global biopharmaceutical company, enabled by a world-class generics business. For over

 

Page 1 of 2

 

 

 


img154009353_2.jpg

img154009353_3.jpg

120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All in for Better Health. To learn more about how, visit www.tevapharm.com.

 

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to attract, hire, integrate and retain highly skilled personnel; our ability to become a high-velocity biopharmaceutical company and to achieve the potential revenue growth from innovative medicines; our ability to deliver on the ambitions and targets for the development of our pipeline assets; our ability to achieve the other ambitions and targets discussed in our R&D Day presentation; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

 

Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries: TevaIR@tevapharm.com

 

 

 

Page 2 of 2

 


Filing Exhibits & Attachments

2 documents

Keep reading